Company Overview and News

8
Axovant Sciences Failed To Mention Critical Information

2018-07-15 seekingalpha - 3
On July 10th 2018 Axovant Sciences (AXON) announced a partnership with Benitec Biopharma (BNTC) for exclusive global rights to BB-301, now named AXO-AAV-OPMD, for the treatment of oculopharyngeal muscular dystrophy, or OPMD, and five additional gene therapy programs in neurological disorders.
BLT OXB BNTC BNIKF OXBDF AXON BNTCW

20
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018

2018-07-12 zacks - 5
Innovation holds the key in the pharma/biotech sector and most companies have been diverting their resources to develop gene therapy candidates in their goal of finding a cure for difficult and incurable diseases. In the first half of 2018, most pharma/biotech bigwigs and also a number of smaller companies scurried for a lucrative catch in the space either through licensing deals or acquisitions.
BOLD VYGR BLT SLDB ADI NVS BNTC BNIKF PFE ONCE AXON BNTCW

5
Has Benitec Biopharma Sold The Jewel In The Crown?

2018-07-11 seekingalpha
Provides Benitec and its major shareholder, Nant, with opportunity to set new corporate direction if it desires to do so.
BLT BNTC BNIKF AXON BNTCW

11
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

2018-07-11 zacks - 1
Positive data released by bigwig Biogen, Inc. (BIIB - Free Report) from a mid-stage study for the treatment of Alzheimer’s disease created a stir in the biotech sector last week. Among other news, Celgene Corporation (CELG - Free Report) reported positive data on a key pipeline candidate from a late-stage study while Axovant (AXON - Free Report) gained on yet another licensing deal.
XLRN CELGZ BIIB IDRAW BLT IDRA CELG BNTC BNIKF BCRX AXON BNTCW

7
Axovant, Benitec Gain on Licensing Deal for Gene Therapy

2018-07-10 zacks
Shares of Axovant Sciences (AXON - Free Report) gained after it announced a licensing agreement with Benitec Biopharma .
UNP BLT SLDB OXB BNTC BNIKF OXBDF AXON BNTCW

5
Axovant Wins With Key Licensing Agreement

2018-07-09 247wallst
Axovant Sciences Ltd. (NASDAQ: AXON) shares saw a handy gain on Monday after the company announced that it has licensed exclusive global rights to an investigational silence-and-replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD).
BLT BNTC BNIKF AXON BNTCW

5
Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders

2018-07-09 genengnews
Benitec Biopharma could generate up to $655 million-plus in payments from licensing its preclinical gene therapy for oculopharyngeal muscular dystrophy (OPMD; pictured), and five additional Benitec gene therapy candidates for neurological disorders to to Axovant Sciences. [NIH]
BLT OXB BNTC BNIKF OXBDF ONCE BNTCW AXON

1
Axovant Significantly Expands Pipeline with Licensing Deal with Benitec BioPharma

2018-07-09 biospace
Axovant, one of Vivek Ramaswamy’s biotech companies best known for its catastrophic Alzheimer’s failure in September 2017, is replenishing its pipeline with a licensing deal with Australian company Benitec BioPharma.
BLT BNTC BNIKF BNTCW

6
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma

2018-07-09 globenewswire - 1
BASEL, Switzerland, July 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD), and has also entered into a research collaboration for the development of five additional gene therapy products in neurological disorders.
BLT BNTC BNIKF AXON BNTCW

 
Benitec Biopharma Ltd. (BNTC) CEO Greg West on Q3 2018 Results - Earnings Call Transcript

2018-06-01 seekingalpha
Thank you for standing by and welcome to the Benitec Biopharma Quarterly Corporate Update Conference Call.
BLT BNTC BNIKF BNTCW

 
Benitec Biopharma Limited (BNIKF) CEO Greg West on Q3 2018 Results - Earnings Call Transcript

2018-06-01 seekingalpha
Thank you for standing by, and welcome to the Benitec Biopharma Quarterly Corporate Update Conference Call.
BLT BNIKF BNTC BNTCW

105
BNTC / Benitec Biopharma Ltd - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-09 fintel.io
Benitec Biopharma Ltd (NASDAQ:BNTC) has 6 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 63,952 shares. Largest shareholders include Morgan Stanley, Susquehanna International Group, Llp, Renaissance Technologies LLC, UBS Group AG, Atlantic Trust Group, LLC, and Bank Of America Corp /de/.
BAC CARA BNIKF BAC BLT UBS BNTC MS ULSGF BNTCW

179
RNAi For Hepatitis B - A False Hope For A Cure?

2018-04-06 seekingalpha - 1
RNAi is a revolutionary and powerful biotech modality that is being utilized for Chronic Hepatitis B.
GILD ARWR SRPT BNIKF DRNA ARCT BIIB BLT JNJ ABUS IONS BNTC ALNY BNTCW

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:BLT / BENITEC BIOPHARMA LIMITED on message board site Silicon Investor.

BioLase Technology, Inc. (BLTI) BioLase Technology, Inc. (BLTI) BioLase Technology, Inc. (BLTI) Cobalt Group-(CBLT) Cobalt Group-(CBLT) Cobalt Group-(CBLT)
BLTD - Beverly Hills Auction BLTD - Beverly Hills Auction BLTD - Beverly Hills Auction